"We are grateful for the strong support from our investors, and based on the significant progress we made over the last 18 months, we were able to raise twice the amount originally anticipated for this second tranche," commented Jim Mahoney, Surface Logix's President and CEO. "Since our last financing round, we completed a Phase 2a trial with SLx-2101, our PDE5 inhibitor. Efficacy assessments showed a potential for clinical benefit with a favorable safety profile. The data also support potential utility in several cardiovascular indications. In addition, we completed a first-time-in-human and a repeat-dose Phase 1 trial for our MTP inhibitor, SLx-4090. With these studies, we demonstrated reductions in post-meal triglyceride and LDL levels and showed that SLx-4090 was well tolerated. With the proceeds from this financing round, we plan to conduct Phase 2a studies with SLx-2101 in Raynaud's Syndrome and Hypertension and a Phase 2a study for SLx-4090 in dyslipidemia."
About Surface Logix Inc.
Surface Logix Inc. uses its expertise in biophysical chemistry to create new small molecule drugs that are optimized to meet the challenges of human physiology. The company is advancing multiple internal programs focused primarily on cardiovascular, metabolic, inflammatory and fibrotic diseases. For more information, please visit http://www.surfacelogix.com.
Contact: Warwick Tong MB ChB Surface Logix Inc. Senior Vice President, Commercial Development 617.746.8505
Media: Kari Watson MacDougall Biomedical Communications Inc. kwatson@macbiocom.com 508.647.0209
Source: Surface Logix Inc.
